Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:02 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Factor In the Initial Resuscitation of Severe Trauma 2 Patients
NCT04534751 · University Health Network, Toronto · PHASE4 · terminated · last registry update 2026-10-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Upon IDSMC's review of interim data, they recommended the trial be stopped based on futility.” | – | Registry record, University Health Network, Toronto |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FGA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-04Phase 3 first posted: China National Center for Cardiovascular Diseases, Alteplase + Standard Anticoagulation (NCT07917078)
- 2026-11-03Phase 3 first posted: Fujian Medical University Union Hospital, Tenecteplase (rhTNK-tPA) (0.25 mg/kg, to maximum of 25mg) (NCT07912970)
- 2026-10-30Phase 3 first posted: University of Calgary, Intravenous Thrombolysis + Tenecteplase/Alteplase- depending upon availability at each treating centre (NCT07906275)
- 2026-09-25Results posted on the registry: Northwestern University, TM5614 (NCT04634799)
- 2026-09-25Also stopped (terminated): Northwestern University, TM5614 (NCT04634799)
- 2026-08-05Phase 3 first posted: Yongjun Wang, rhTNK-tPA (0.25mg/kg) + Reteplase 10 Units (U) plus a second dose of reteplase 10 U (NCT07748039)
- 2026-07-27Phase 3 first posted: 115 People's Hospital, Alteplase (NCT07727395)
- 2026-07-07Phase 3 first posted: University of Calgary, Tenecteplase or Alteplase- depending upon availability at each treating centre (NCT07687056)
- 2026-06-25Phase 3 first posted: The First Affiliated Hospital with Nanjing Medical University, Recombinant Tissue Plasminogen Activator (rt-PA) + Best Medical Management (NCT07668323)
- 2026-06-01Also stopped (terminated): Vanderbilt University, Bradykinin (NCT00868855)
- 2026-05-26Phase 3 first posted: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Tenecteplase (rhTNK-tPA) (0.25 mg/kg, to maximum of 25mg) + Standard medical treatment (NCT07606807)
- 2026-05-22Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Intravenous administration (NCT07603440)
- 2026-05-18Also stopped (terminated): University Hospital Tuebingen, Tenecteplase (until trial protocol V04: Alteplase) (NCT04965038)
- 2026-05-13Phase 3 first posted: Cardiocentro Ticino, Clopidogrel + Ticagrelor (NCT07582835)
- 2026-04-29Also stopped (withdrawn): Centre hospitalier de l'Université de Montréal (CHUM), a drug against FGA (NCT06034847)
- 2026-04-20Phase 3 first posted: The First Affiliated Hospital of Zhengzhou University, TNK-tPA + Aspirin (NCT07540416)
- 2026-04-14Also stopped (terminated): Kaiser Permanente, normal saline + TNK (Tenecteplase) (NCT01580618)
- 2026-03-17Phase 3 first posted: First Affiliated Hospital of Guangxi Medical University, Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg) (NCT07475949)
- 2026-03-17Phase 3 first posted: First Hospital of China Medical University, Tenecteplase (0.25mg/kg) + Standard Medical Management (NCT07476898)
- 2026-03-13Phase 3 first posted: Beijing Tiantan Hospital, Standard medical treatment (NCT07471256)
- 2026-03-13Phase 3 first posted: Chuansheng Zhao, Tenecteplase (0.0938mg/kg) + Placebo (NCT07471282)
- 2026-01-23Phase 3 first posted: Boehringer Ingelheim, Tenecteplase + Standard of care treatment (NCT07361302)
- 2025-12-24Phase 3 first posted: Xiang Luo, Standard medical treatment (NCT07302854)
- 2025-11-28Phase 3 first posted: Xuanwu Hospital, Beijing, Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg) (NCT07253181)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision